ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Joachim Eeckhout contributed 195 entries already.
At the IZB in Martinsried, Invitris is developing a cell-free platform to turn digital sequences into proteins, antibodies and phages within hours. CEO Patrick Grossmann explains why AI is shifting the bottleneck from drug design to manufacturing, how Phactory™ addresses phage production and why microgravity could open new possibilities.
Beyond the main headlines, European biotech kept moving this week. This edition of Meanwhile in Biotech covers cancer vaccine follow-up, changes to kidney and obesity trials, and two developments in AI-enabled drug discovery. Here are six updates worth catching up on.
British rare disease specialist Ambrose Healthcare has acquired Dutch biotech AM-Pharma for up to €161 million, adding an enzyme replacement therapy to its pipeline and a development base in Utrecht.
Helping biopharmaceutical innovators build scalable, manufacturable, and commercially viable processes from the start.
Following Fresenius’ launch of a €200 million healthcare venture fund in July, we invited Thomas Thestrup, managing director of Fresenius Ventures, to share his perspective in the Autumn issue of European Biotechnology. His argument: Europe has the innovation and the corporate investment expertise to compete globally, but needs more capital from its own healthcare companies to prevent the value created by European science from moving elsewhere. Here’s what he had to say:
French biotech OSE Immunotherapeutics has reported higher one-year survival rates with two combinations of its cancer vaccine Tedopi compared with chemotherapy alone in a Phase 2 lung cancer trial. However, the results are similar to those previously achieved with Tedopi alone, raising questions about the added benefit of combination treatment.
Each month, the European Medicines Agency’s human medicines committee (CHMP) weighs in on which drugs should reach European patients — and which should not. Here are eight decisions from its October meeting worth knowing.
Swiss biotech Nouscom has raised €120 million in an oversubscribed Series D financing to advance NOUS-209, an experimental cancer vaccine designed to prevent tumors in people with Lynch syndrome, into a global registration-enabling clinical trial. Alongside the financing, the company has released new long-term clinical data showing encouraging signs of cancer prevention.
French-Belgian biotech Osivax has reported disappointing Phase 2b results for its broad-spectrum influenza vaccine OVX836, which achieved a nonsignificant efficacy estimate of 24% against a predefined target of 50%. The company is now emphasizing a strategy to combine its candidate with existing seasonal flu vaccines.
Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: a swift scientific leadership change at Evotec, a broader reshuffle at Sibylla and a new CEO to guide AL-S Pharma toward Phase 3.